Endocannabinoid Hydrolase Inhibitors: Potential Novel Anxiolytic Drugs

References

• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5^®). American Psychiatric Publisher; 2013.
   Google Scholar
• Szuhany KL, Simon NM. Anxiety disorders: a review. JAMA. 2022;328(24):2431–2445. doi:10.1001/jama.2022.22744
   PubMed Web of Science ®Google Scholar
• Huang Y, Wang Y, Wang H, et al. Prevalence of mental disorders in China: a cross-sectional epidemiological study. Lancet Psychiatry. 2019;6(3):211–224. doi:10.1016/S2215-0366(18)30511-X
   PubMed Web of Science ®Google Scholar
• Inserra A, Piot A, De Gregorio D, Gobbi G. Lysergic Acid Diethylamide (LSD) for the treatment of anxiety disorders: preclinical and clinical evidence. CNS Drugs. 2023;37(9):733–754. doi:10.1007/s40263-023-01008-5
   PubMed Web of Science ®Google Scholar
• Skolnick P. Anxioselective anxiolytics: on a quest for the Holy Grail. Trends Pharmacol Sci. 2012;33(11):611–620. doi:10.1016/j.tips.2012.08.003
   PubMed Web of Science ®Google Scholar
• Gosmann NP, de Abreu Costa M, de Barros Jaeger M, et al. Selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for anxiety, obsessive-compulsive, and stress disorders: a 3-level network meta-analysis. PLoS Med. 2021;18(6):e1003664. doi:10.1371/journal.pmed.1003664
   PubMed Web of Science ®Google Scholar
• Murphy SE, Capitão LP, Giles SLC, Cowen PJ, Stringaris A, Harmer CJ. The knowns and unknowns of SSRI treatment in young people with depression and anxiety: efficacy, predictors, and mechanisms of action. Lancet Psychiatry. 2021;8(9):824–835. doi:10.1016/S2215-0366(21)00154-1
   PubMed Web of Science ®Google Scholar
• Gosmann NP, de Abreu Costa M, de Barros Jaeger M, et al. Incidence of adverse events and comparative tolerability of selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for the treatment of anxiety, obsessive-compulsive, and stress disorders: a systematic review and network meta-analysis. Psychol Med. 2023;53(9):3783–3792. doi:10.1017/S0033291723001630
   PubMed Web of Science ®Google Scholar
• Joffe H, Petrillo L, Viguera A, et al. Eszopiclone improves insomnia and depressive and anxious symptoms in perimenopausal and postmenopausal women with hot flashes: a randomized, double-blinded, placebo-controlled crossover trial. Am J Obstet Gynecol. 2010;202(2):171.e1–171.e11. doi:10.1016/j.ajog.2009.10.868
   PubMed Web of Science ®Google Scholar
• Mokhber N, Azarpazhooh MR, Khajehdaluee M, Velayati A, Hopwood M. Randomized, single-blind, trial of sertraline and buspirone for treatment of elderly patients with generalized anxiety disorder. Psychiatry Clin Neurosci. 2010;64(2):128–133. doi:10.1111/j.1440-1819.2009.02055.x
   PubMed Web of Science ®Google Scholar
• Lowe H, Toyang N, Steele B, Bryant J, Ngwa W. The endocannabinoid system: a potential target for the treatment of various diseases. Int J Mol Sci. 2021;22(17):9472. doi:10.3390/ijms22179472
   PubMed Web of Science ®Google Scholar
• Alcaraz-Silva J, Feingold D, Viana-Torre G, et al. The endocannabinoid system as a biomarker for diagnostic and therapeutic applications in depression and anxiety. CNS Neurol Disord Drug Targets. 2023;22(3):417–430. doi:10.2174/1871527321666220405114402
   PubMed Web of Science ®Google Scholar
• Schmidt ME, Liebowitz MR, Stein MB, et al. The effects of inhibition of fatty acid amide hydrolase (FAAH) by JNJ-42165279 in social anxiety disorder: a double-blind, randomized, placebo-controlled proof-of-concept study. Neuropsychopharmacology. 2021;46(5):1004–1010. doi:10.1038/s41386-020-00888-1
   PubMed Web of Science ®Google Scholar
• Cristino L, Bisogno T, Di Marzo V. Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat Rev Neurol. 2020;16(1):9–29. doi:10.1038/s41582-019-0284-z
   PubMed Web of Science ®Google Scholar
• Murkar A, De Koninck J, Merali Z. Cannabinoids: revealing their complexity and role in central networks of fear and anxiety. Neurosci Biobehav Rev. 2021;131:30–46. doi:10.1016/j.neubiorev.2021.09.002
   PubMed Web of Science ®Google Scholar
• Kaczocha M, Haj-Dahmane S. Mechanisms of endocannabinoid transport in the brain. Br J Pharmacol. 2022;179(17):4300–4310. doi:10.1111/bph.15469
   PubMed Web of Science ®Google Scholar
• Petrie GN, Nastase AS, Aukema RJ, Hill MN. Endocannabinoids, cannabinoids and the regulation of anxiety. Neuropharmacology. 2021;195:108626. doi:10.1016/j.neuropharm.2021.108626
   PubMed Web of Science ®Google Scholar
• Morgan AJ, Kingsley PJ, Mitchener MM, et al. Detection of cyclooxygenase-2-derived oxygenation products of the endogenous cannabinoid 2-arachidonoylglycerol in mouse brain. ACS Chem Neurosci. 2018;9(7):1552–1559. doi:10.1021/acschemneuro.7b00499
   PubMed Web of Science ®Google Scholar
• Patel S, Hill MN, Cheer JF, Wotjak CT, Holmes A. The endocannabinoid system as a target for novel anxiolytic drugs. Neurosci Biobehav Rev. 2017;76(Pt A):56–66. doi:10.1016/j.neubiorev.2016.12.033
   PubMedGoogle Scholar
• Maldonado R, Cabañero D, Martín-García E. The endocannabinoid system in modulating fear, anxiety, and stress. Dialogues Clin Neurosci. 2020;22(3):229–239. doi:10.31887/DCNS.2020.22.3/rmaldonado
   PubMed Web of Science ®Google Scholar
• Lama A, Pirozzi C, Severi I, et al. Palmitoylethanolamide dampens neuroinflammation and anxiety-like behavior in obese mice. Brain Behav Immun. 2022;102:110–123. doi:10.1016/j.bbi.2022.02.008
   PubMed Web of Science ®Google Scholar
• Fraguas-Sánchez AI, Torres-Suárez AI. Medical Use of Cannabinoids. Drugs. 2018;78(16):1665–1703. doi:10.1007/s40265-018-0996-1
   PubMed Web of Science ®Google Scholar
• Cohen K, Weizman A, Weinstein A. Positive and negative effects of cannabis and cannabinoids on health. Clin Pharmacol Ther. 2019;105(5):1139–1147. doi:10.1002/cpt.1381
   PubMed Web of Science ®Google Scholar
• Stasiulewicz A, Znajdek K, Grudzień M, Pawiński T, Sulkowska AJI. A Guide to Targeting the Endocannabinoid System in Drug Design. Int J Mol Sci. 2020;21(8):2778. doi:10.3390/ijms21082778
   PubMed Web of Science ®Google Scholar
• Gipson CD, Kupchik YM, Kalivas PW. Rapid, transient synaptic plasticity in addiction. Neuropharmacology. 2014;76(Pt B):276–286. doi:10.1016/j.neuropharm.2013.04.032
   PubMedGoogle Scholar
• Hill MN, Bierer LM, Makotkine I, et al. Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the World Trade Center attacks. Psychoneuroendocrinology. 2013;38(12):2952–2961. doi:10.1016/j.psyneuen.2013.08.004
   PubMed Web of Science ®Google Scholar
• Siebers M, Biedermann SV, Bindila L, Lutz B, Fuss J. Exercise-induced euphoria and anxiolysis do not depend on endogenous opioids in humans. Psychoneuroendocrinology. 2021;126:105173. doi:10.1016/j.psyneuen.2021.105173
   PubMed Web of Science ®Google Scholar
• Shonesy BC, Bluett RJ, Ramikie TS, et al. Genetic disruption of 2-arachidonoylglycerol synthesis reveals a key role for endocannabinoid signaling in anxiety modulation. Cell Rep. 2014;9(5):1644–1653. doi:10.1016/j.celrep.2014.11.001
   PubMed Web of Science ®Google Scholar
• Jenniches I, Ternes S, Albayram O, et al. Anxiety, stress, and fear response in mice with reduced endocannabinoid levels. Biol Psychiatry. 2016;79(10):858–868. doi:10.1016/j.biopsych.2015.03.033
   PubMed Web of Science ®Google Scholar
• Sánchez-Marín L, Flores-López M, Pastor A, et al. Acute stress and alcohol exposure during adolescence result in an anxious phenotype in adulthood: role of altered glutamate/endocannabinoid transmission mechanisms. Prog Neuropsychopharmacol Biol Psychiatry. 2022;113:110460. doi:10.1016/j.pnpbp.2021.110460
   PubMed Web of Science ®Google Scholar
• Hill MN, Haney M, Hillard CJ, Karhson DS, Vecchiarelli HA. The endocannabinoid system as a putative target for the development of novel drugs for the treatment of psychiatric illnesses. Psychol Med. 2023;53(15):7006–7024. doi:10.1017/S0033291723002465
   PubMed Web of Science ®Google Scholar
• Marcus DJ, Bedse G, Gaulden AD, et al. Endocannabinoid signaling collapse mediates stress-induced amygdalo-cortical strengthening. Neuron. 2020;105(6):1062–1076.e6. doi:10.1016/j.neuron.2019.12.024
   PubMed Web of Science ®Google Scholar
• Guggenhuber S, Romo-Parra H, Bindila L, et al. Impaired 2-AG signaling in hippocampal glutamatergic neurons: aggravation of anxiety-like behavior and unaltered seizure susceptibility. Int J Neuropsychopharmacol. 2015;19(2):pyv091. doi:10.1093/ijnp/pyv091
   PubMed Web of Science ®Google Scholar
• Serrano A, Pavon FJ, Buczynski MW, et al. Deficient endocannabinoid signaling in the central amygdala contributes to alcohol dependence-related anxiety-like behavior and excessive alcohol intake. Neuropsychopharmacology. 2018;43(9):1840–1850. doi:10.1038/s41386-018-0055-3
   PubMed Web of Science ®Google Scholar
• Pavón FJ, Polis IY, Stouffer DG, et al. Selective inhibition of monoacylglycerol lipase is associated with passive coping behavior and attenuation of stress-induced dopamine release in the medial prefrontal cortex. Neurobiol Stress. 2021;14:100293. doi:10.1016/j.ynstr.2021.100293
   PubMed Web of Science ®Google Scholar
• Alteba S, Mizrachi Zer-Aviv T, Tenenhaus A, et al. Antidepressant-like effects of URB597 and JZL184 in male and female rats exposed to early life stress. Eur Neuropsychopharmacol. 2020;39:70–86. doi:10.1016/j.euroneuro.2020.08.005
   PubMed Web of Science ®Google Scholar
• Bedse G, Bluett RJ, Patrick TA, et al. Therapeutic endocannabinoid augmentation for mood and anxiety disorders: comparative profiling of FAAH, MAGL and dual inhibitors. Transl Psychiatry. 2018;8(1):92. doi:10.1038/s41398-018-0141-7
   PubMed Web of Science ®Google Scholar
• Bedse G, Hartley ND, Neale E, et al. Functional redundancy between canonical endocannabinoid signaling systems in the modulation of anxiety. Biol Psychiatry. 2017;82(7):488–499. doi:10.1016/j.biopsych.2017.03.002
   PubMed Web of Science ®Google Scholar
• Bosch-Bouju C, Larrieu T, Linders L, Manzoni OJ, Layé S. Endocannabinoid-mediated plasticity in nucleus accumbens controls vulnerability to anxiety after social defeat stress. Cell Rep. 2016;16(5):1237–1242. doi:10.1016/j.celrep.2016.06.082
   PubMed Web of Science ®Google Scholar
• Lomazzo E, Bindila L, Remmers F, et al. Therapeutic potential of inhibitors of endocannabinoid degradation for the treatment of stress-related hyperalgesia in an animal model of chronic pain. Neuropsychopharmacology. 2015;40(2):488–501. doi:10.1038/npp.2014.198
   PubMed Web of Science ®Google Scholar
• Sumislawski JJ, Ramikie TS, Patel S. Reversible gating of endocannabinoid plasticity in the amygdala by chronic stress: a potential role for monoacylglycerol lipase inhibition in the prevention of stress-induced behavioral adaptation. Neuropsychopharmacology. 2011;36(13):2750–2761. doi:10.1038/npp.2011.166
   PubMed Web of Science ®Google Scholar
• Kinsey SG, O’Neal ST, Long JZ, Cravatt BF, Lichtman AH. Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay. Pharmacol Biochem Behav. 2011;98(1):21–27. doi:10.1016/j.pbb.2010.12.002
   PubMed Web of Science ®Google Scholar
• Worley NB, Varela JA, Gaillardetz GP, Hill MN, Christianson JP. Monoacylglycerol lipase alpha inhibition alters prefrontal cortex excitability and blunts the consequences of traumatic stress in rat. Neuropharmacology. 2020;166:107964. doi:10.1016/j.neuropharm.2020.107964
   PubMed Web of Science ®Google Scholar
• Vozella V, Cruz B, Feldman HC, et al. Sexually dimorphic effects of monoacylglycerol lipase inhibitor MJN110 on stress-related behavior and drinking in Marchigian Sardinian alcohol-preferring rats. Br J Pharmacol. 2023;180(24):3130–3145. doi:10.1111/bph.16197
   PubMed Web of Science ®Google Scholar
• Dlugos A, Childs E, Stuhr KL, Hillard CJ, de Wit H. Acute stress increases circulating anandamide and other N-acylethanolamines in healthy humans. Neuropsychopharmacology. 2012;37(11):2416–2427. doi:10.1038/npp.2012.100
   PubMed Web of Science ®Google Scholar
• Zhai Q, Islam A, Chen B, et al. Endocannabinoid 2-arachidonoylglycerol levels in the anterior cingulate cortex, caudate putamen, nucleus accumbens, and piriform cortex were upregulated by chronic restraint stress. Cells. 2023;12(3):393. doi:10.3390/cells12030393
   PubMed Web of Science ®Google Scholar
• Di S, Itoga CA, Fisher MO, et al. Acute stress suppresses synaptic inhibition and increases anxiety via endocannabinoid release in the basolateral amygdala. J Neurosci. 2016;36(32):8461–8470. doi:10.1523/JNEUROSCI.2279-15.2016
   PubMed Web of Science ®Google Scholar
• Imperatore R, Morello G, Luongo L, et al. Genetic deletion of monoacylglycerol lipase leads to impaired cannabinoid receptor CB₁R signaling and anxiety-like behavior. J Neurochem. 2015;135(4):799–813. doi:10.1111/jnc.13267
   PubMed Web of Science ®Google Scholar
• Schlosburg JE, Blankman JL, Long JZ, et al. Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat Neurosci. 2010;13(9):1113–1119. doi:10.1038/nn.2616
   PubMed Web of Science ®Google Scholar
• Kenwood MM, Kalin NH, Barbas H. The prefrontal cortex, pathological anxiety, and anxiety disorders. Neuropsychopharmacology. 2022;47(1):260–275. doi:10.1038/s41386-021-01109-z
   PubMed Web of Science ®Google Scholar
• Liu WZ, Zhang WH, Zheng ZH, et al. Identification of a prefrontal cortex-to-amygdala pathway for chronic stress-induced anxiety. Nat Commun. 2020;11(1):2221. doi:10.1038/s41467-020-15920-7
   PubMed Web of Science ®Google Scholar
• Domoto M, Sasase H, Wada S, et al. The synthetic cannabinoid 5F-AMB changes the balance between excitation and inhibition of layer V pyramidal neurons in the mouse medial prefrontal cortex. Psychopharmacology. 2018;235(8):2367–2376. doi:10.1007/s00213-018-4933-5
   PubMed Web of Science ®Google Scholar
• Zhang WH, Zhang JY, Holmes A, Pan BX. Amygdala Circuit Substrates for Stress Adaptation and Adversity. Biol Psychiatry. 2021;89(9):847–856. doi:10.1016/j.biopsych.2020.12.026
   PubMed Web of Science ®Google Scholar
• Jiang S, Zheng C, Wen G, Bu B, Zhao S, Xu X. Down-regulation of NR2B receptors contributes to the analgesic and antianxiety effects of enriched environment mediated by endocannabinoid system in the inflammatory pain mice. Behav Brain Res. 2022;435:114062. doi:10.1016/j.bbr.2022.114062
   PubMed Web of Science ®Google Scholar
• Longaretti A, Forastieri C, Gabaglio M, Rubino T, Battaglioli E, Rusconi F. Termination of acute stress response by the endocannabinoid system is regulated through lysine-specific demethylase 1-mediated transcriptional repression of 2-AG hydrolases ABHD6 and MAGL. J Neurochem. 2020;155(1):98–110. doi:10.1111/jnc.15000
   PubMed Web of Science ®Google Scholar
• Vickstrom CR, Liu X, Liu S, et al. Role of endocannabinoid signaling in a septohabenular pathway in the regulation of anxiety- and depressive-like behavior. Mol Psychiatry. 2021;26(7):3178–3191. doi:10.1038/s41380-020-00905-1
   PubMed Web of Science ®Google Scholar
• Biltz RG, Sawicki CM, Sheridan JF, Godbout JP. The neuroimmunology of social-stress-induced sensitization. Nat Immunol. 2022;23(11):1527–1535. doi:10.1038/s41590-022-01321-z
   PubMed Web of Science ®Google Scholar
• Pasquarelli N, Porazik C, Hanselmann J, Weydt P, Ferger B, Witting A. Comparative biochemical characterization of the monoacylglycerol lipase inhibitor KML29 in brain, spinal cord, liver, spleen, fat and muscle tissue. Neuropharmacology. 2015;91:148–156. doi:10.1016/j.neuropharm.2014.12.001
   PubMed Web of Science ®Google Scholar
• Wenzel TJ, Klegeris A. Novel multi-target directed ligand-based strategies for reducing neuroinflammation in Alzheimer’s disease. Life Sci. 2018;207:314–322. doi:10.1016/j.lfs.2018.06.025
   PubMed Web of Science ®Google Scholar
• Kerr DM, Harhen B, Okine BN, Egan LJ, Finn DP, Roche M. The monoacylglycerol lipase inhibitor JZL184 attenuates LPS-induced increases in cytokine expression in the rat frontal cortex and plasma: differential mechanisms of action. Br J Pharmacol. 2013;169(4):808–819. doi:10.1111/j.1476-5381.2012.02237.x
   PubMed Web of Science ®Google Scholar
• Zhu D, Zhang J, Hashem J, Gao F, Chen C. Inhibition of 2-arachidonoylglycerol degradation enhances glial immunity by single-cell transcriptomic analysis. J Neuroinflammation. 2023;20(1):17. doi:10.1186/s12974-023-02701-4
   PubMed Web of Science ®Google Scholar
• Grabner GF, Eichmann TO, Wagner B, et al. Deletion of monoglyceride lipase in astrocytes attenuates lipopolysaccharide-induced neuroinflammation. J Biol Chem. 2016;291(2):913–923. doi:10.1074/jbc.M115.683615
   PubMed Web of Science ®Google Scholar
• Nomura DK, Morrison BE, Blankman JL, et al. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science. 2011;334(6057):809–813. doi:10.1126/science.1209200
   PubMed Web of Science ®Google Scholar
• Alhouayek M, Masquelier J, Cani PD, Lambert DM, Muccioli GG. Implication of the anti-inflammatory bioactive lipid prostaglandin D2-glycerol ester in the control of macrophage activation and inflammation by ABHD6. Proc Natl Acad Sci U S A. 2013;110(43):17558–17563. doi:10.1073/pnas.1314017110
   PubMed Web of Science ®Google Scholar
• Kibret BG, Ishiguro H, Horiuchi Y, Onaivi ES. New insights and potential therapeutic targeting of CB2 cannabinoid receptors in CNS disorders. Int J Mol Sci. 2022;23(2):975. doi:10.3390/ijms23020975
   PubMed Web of Science ®Google Scholar
• Li J, Wang H, Liu D, et al. CB2R activation ameliorates late adolescent chronic alcohol exposure-induced anxiety-like behaviors during withdrawal by preventing morphological changes and suppressing NLRP3 inflammasome activation in prefrontal cortex microglia in mice. Brain Behav Immun. 2023;110:60–79. doi:10.1016/j.bbi.2023.02.001
   PubMed Web of Science ®Google Scholar
• Mecha M, Feliú A, Carrillo-Salinas FJ, et al. Endocannabinoids drive the acquisition of an alternative phenotype in microglia. Brain Behav Immun. 2015;49:233–245. doi:10.1016/j.bbi.2015.06.002
   PubMed Web of Science ®Google Scholar
• Young AP, Denovan-Wright EM. The dynamic role of microglia and the endocannabinoid system in neuroinflammation. Front Pharmacol. 2021;12:806417. doi:10.3389/fphar.2021.806417
   PubMed Web of Science ®Google Scholar
• Roberts CJ, Stuhr KL, Hutz MJ, Raff H, Hillard CJ. Endocannabinoid signaling in hypothalamic-pituitary-adrenocortical axis recovery following stress: effects of indirect agonists and comparison of male and female mice. Pharmacol Biochem Behav. 2014;117:17–24. doi:10.1016/j.pbb.2013.11.026
   PubMed Web of Science ®Google Scholar
• Aliczki M, Zelena D, Mikics E, et al. Monoacylglycerol lipase inhibition-induced changes in plasma corticosterone levels, anxiety and locomotor activity in male CD1 mice. Horm Behav. 2013;63(5):752–758. doi:10.1016/j.yhbeh.2013.03.017
   PubMed Web of Science ®Google Scholar
• Hill MN, McLaughlin RJ, Pan B, et al. Recruitment of prefrontal cortical endocannabinoid signaling by glucocorticoids contributes to termination of the stress response. J Neurosci. 2011;31(29):10506–10515. doi:10.1523/JNEUROSCI.0496-11.2011
   PubMed Web of Science ®Google Scholar
• Long JZ, Li W, Booker L, et al. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol. 2009;5(1):37–44. doi:10.1038/nchembio.129
   PubMed Web of Science ®Google Scholar
• Yamasaki T, Hatori A, Zhang Y, et al. Neuroprotective effects of minocycline and KML29, a potent inhibitor of monoacylglycerol lipase, in an experimental stroke model: a small-animal positron emission tomography study. Theranostics. 2021;11(19):9492–9502. doi:10.7150/thno.64320
   PubMed Web of Science ®Google Scholar
• Della Pietra A, Giniatullin R, Savinainen JR. Distinct activity of endocannabinoid-hydrolyzing enzymes MAGL and FAAH in key regions of peripheral and central nervous system implicated in migraine. Int J Mol Sci. 2021;22(3):1204. doi:10.3390/ijms22031204
   PubMed Web of Science ®Google Scholar
• Chanda PK, Gao Y, Mark L, et al. Monoacylglycerol lipase activity is a critical modulator of the tone and integrity of the endocannabinoid system. Mol Pharmacol. 2010;78(6):996–1003. doi:10.1124/mol.110.068304
   PubMed Web of Science ®Google Scholar
• Aaltonen N, Kedzierska E, Orzelska-Górka J, et al. In Vivo Characterization of the Ultrapotent Monoacylglycerol Lipase Inhibitor {4-[bis-(benzo[d][1,3]dioxol-5-yl)methyl]-piperidin-1-yl}(1H-1,2,4-triazol-1-yl)methanone (JJKK-048). J Pharmacol Exp Ther. 2016;359(1):62–72. doi:10.1124/jpet.116.233114
   PubMed Web of Science ®Google Scholar
• Aida J, Fushimi M, Kusumoto T, et al. Design, synthesis, and evaluation of piperazinyl pyrrolidin-2-ones as a novel series of reversible monoacylglycerol lipase inhibitors. J Med Chem. 2018;61(20):9205–9217. doi:10.1021/acs.jmedchem.8b00824
   PubMed Web of Science ®Google Scholar
• Xiang H, Wang Y, Yang L, et al. Novel MAGL inhibitors alleviate LPS-induced acute kidney injury by inhibiting NLRP3 inflammatory vesicles, modulating intestinal flora, repairing the intestinal barrier, and interfering with serum metabolism. Molecules. 2023;28(21):7245. doi:10.3390/molecules28217245
   PubMed Web of Science ®Google Scholar
• Afzal O, Kumar S, Kumar R, Firoz A, Jaggi M, Bawa S. Docking based virtual screening and molecular dynamics study to identify potential monoacylglycerol lipase inhibitors. Bioorg Med Chem Lett. 2014;24(16):3986–3996. doi:10.1016/j.bmcl.2014.06.029
   PubMed Web of Science ®Google Scholar
• Xiong F, Ding X, Zhang H, et al. Discovery of novel reversible monoacylglycerol lipase inhibitors via docking-based virtual screening. Bioorg Med Chem Lett. 2021;41:127986. doi:10.1016/j.bmcl.2021.127986
   PubMed Web of Science ®Google Scholar
• Tuccinardi T, Granchi C, Rizzolio F, et al. Identification and characterization of a new reversible MAGL inhibitor. Bioorg Med Chem. 2014;22(13):3285–3291. doi:10.1016/j.bmc.2014.04.057
   PubMed Web of Science ®Google Scholar
• Zhi Z, Zhang W, Yao J, et al. Discovery of Aryl formyl piperidine derivatives as potent, reversible, and selective monoacylglycerol lipase inhibitors. J Med Chem. 2020;63(11):5783–5796. doi:10.1021/acs.jmedchem.9b02137
   PubMed Web of Science ®Google Scholar
• Bononi G, Di Stefano M, Poli G, et al. Reversible monoacylglycerol lipase inhibitors: discovery of a new class of benzylpiperidine derivatives. J Med Chem. 2022;65(10):7118–7140. doi:10.1021/acs.jmedchem.1c01806
   PubMed Web of Science ®Google Scholar
• Di Stefano M, Masoni S, Bononi G, et al. Design, synthesis, ADME and biological evaluation of benzylpiperidine and benzylpiperazine derivatives as novel reversible monoacylglycerol lipase (MAGL) inhibitors. Eur J Med Chem. 2024;263:115916. doi:10.1016/j.ejmech.2023.115916
   PubMed Web of Science ®Google Scholar
• Bononi G, Tonarini G, Poli G, et al. Monoacylglycerol lipase (MAGL) inhibitors based on a diphenylsulfide-benzoylpiperidine scaffold. Eur J Med Chem. 2021;223:113679. doi:10.1016/j.ejmech.2021.113679
   PubMed Web of Science ®Google Scholar
• Kapanda CN, Muccioli GG, Labar G, Poupaert JH, Lambert DM. Bis(dialkylaminethiocarbonyl)disulfides as potent and selective monoglyceride lipase inhibitors. J Med Chem. 2009;52(22):7310–7314. doi:10.1021/jm901323s
   PubMed Web of Science ®Google Scholar
• Omran Z. New Disulfiram Derivatives as MAGL-Selective Inhibitors. Molecules. 2021;26(11):3296. doi:10.3390/molecules26113296
   PubMed Web of Science ®Google Scholar
• Andrei C, Mihai DP, Nitulescu G, et al. Cetirizine and levetiracetam as inhibitors of monoacylglycerol lipase: investigating their repurposing potential as novel osteoarthritic pain therapies. Pharmaceuticals. 2023;16(11):1563. doi:10.3390/ph16111563
   Web of Science ®Google Scholar
• Jiang M, Huizenga MCW, Wirt JL, et al. A monoacylglycerol lipase inhibitor showing therapeutic efficacy in mice without central side effects or dependence. Nat Commun. 2023;14(1):8039. doi:10.1038/s41467-023-43606-3
   PubMed Web of Science ®Google Scholar
• Adeel M, Saorin G, Boccalon G, et al. A carrier free delivery system of a monoacylglycerol lipase hydrophobic inhibitor. Int J Pharm. 2022;613:121374. doi:10.1016/j.ijpharm.2021.121374
   PubMedGoogle Scholar
• Deng H, Li W. Monoacylglycerol lipase inhibitors: modulators for lipid metabolism in cancer malignancy, neurological and metabolic disorders. Acta Pharm Sin B. 2020;10(4):582–602. doi:10.1016/j.apsb.2019.10.006
   PubMed Web of Science ®Google Scholar
• Cisar JS, Weber OD, Clapper JR, et al. Identification of ABX-1431, a selective inhibitor of monoacylglycerol lipase and clinical candidate for treatment of neurological disorders. J Med Chem. 2018;61(20):9062–9084. doi:10.1021/acs.jmedchem.8b00951
   PubMed Web of Science ®Google Scholar
• Deng H, Zhang Q, Lei Q, et al. Discovering monoacylglycerol lipase inhibitors by a combination of fluorogenic substrate assay and activity-based protein profiling. Front Pharmacol. 2022;13:941522. doi:10.3389/fphar.2022.941522
   PubMed Web of Science ®Google Scholar
• Punt JM, van der Vliet D, van der Stelt M. Chemical probes to control and visualize lipid metabolism in the brain. Acc Chem Res. 2022;55(22):3205–3217. doi:10.1021/acs.accounts.2c00521
   PubMed Web of Science ®Google Scholar
• Takahata K, Seki C, Kimura Y, et al. First-in-human in vivo imaging and quantification of monoacylglycerol lipase in the brain: a PET study with 18F-T-401. Eur J Nucl Med Mol Imaging. 2022;49(9):3150–3161. doi:10.1007/s00259-021-05671-y
   PubMed Web of Science ®Google Scholar
• He Y, Grether U, Taddio MF, et al. Multi-parameter optimization: development of a morpholin-3-one derivative with an improved kinetic profile for imaging monoacylglycerol lipase in the brain. Eur J Med Chem. 2022;243:114750. doi:10.1016/j.ejmech.2022.114750
   PubMed Web of Science ®Google Scholar
• Cheng R, Fujinaga M, Yang J, et al. A novel monoacylglycerol lipase-targeted 18F-labeled probe for positron emission tomography imaging of brown adipose tissue in the energy network. Acta Pharmacol Sin. 2022;43(11):3002–3010. doi:10.1038/s41401-022-00912-8
   PubMed Web of Science ®Google Scholar
• King AR, Dotsey EY, Lodola A, et al. Discovery of potent and reversible monoacylglycerol lipase inhibitors. Chem Biol. 2009;16(10):1045–1052. doi:10.1016/j.chembiol.2009.09.012
   PubMedGoogle Scholar
• Al-Romaiyan A, Masocha W. Pristimerin, a triterpene that inhibits monoacylglycerol lipase activity, prevents the development of paclitaxel-induced allodynia in mice. Front Pharmacol. 2022;13:944502. doi:10.3389/fphar.2022.944502
   PubMed Web of Science ®Google Scholar
• Merali Z, Cayer C, Kent P, et al. Sacred Maya incense, copal (Protium copal - Burseraceae), has antianxiety effects in animal models. J Ethnopharmacol. 2018;216:63–70. doi:10.1016/j.jep.2018.01.027
   PubMed Web of Science ®Google Scholar
• Tung M-C, Fung K-M, Hsu H-M, Tseng T-S. Discovery of 8-prenylnaringenin from hop (Humulus lupulus L.) as a potent monoacylglycerol lipase inhibitor for treatments of neuroinflammation and Alzheimer’s disease. RSC Adv. 2021;11(49):31062–31072. doi:10.1039/d1ra05311f
   PubMed Web of Science ®Google Scholar
• El-Alfy AT, Joseph S, Brahmbhatt A, Akati S, Abourashed EA. Indirect modulation of the endocannabinoid system by specific fractions of nutmeg total extract. Pharm Biol. 2016;54(12):2933–2938. doi:10.1080/13880209.2016.1194864
   PubMed Web of Science ®Google Scholar
• Benkherouf AY, Soini SL, Stompor M, Uusi-Oukari M. Positive allosteric modulation of native and recombinant GABAA receptors by hops prenylflavonoids. Eur J Pharmacol. 2019;852:34–41. doi:10.1016/j.ejphar.2019.02.034
   PubMed Web of Science ®Google Scholar
• Beladjila KA, Berrehal D, De Tommasi N, et al. New phenylethanoid glycosides from cistanche phelypaea and their activity as inhibitors of Monoacylglycerol Lipase (MAGL). Planta Med. 2018;84(9–10):710–715. doi:10.1055/s-0044-100187
   PubMed Web of Science ®Google Scholar
• De Leo M, Huallpa CG, Alvarado B, et al. New diterpenes from Salvia pseudorosmarinus and their activity as inhibitors of monoacylglycerol lipase (MAGL). Fitoterapia. 2018;130:251–258. doi:10.1016/j.fitote.2018.09.010
   PubMed Web of Science ®Google Scholar
• Mei J, Guo R, Zhang F, et al. Identification of bioactive natural products using yeast: application to monoacylglycerol lipase inhibitor extraction from Corydalis Rhizoma. Biomed Pharmacother. 2022;149:112798. doi:10.1016/j.biopha.2022.112798
   PubMed Web of Science ®Google Scholar
• Chen L, Yan Y, Chen T, et al. Forsythiaside prevents β-amyloid-induced hippocampal slice injury by upregulating 2-arachidonoylglycerol via cannabinoid receptor 1-dependent NF-κB pathway. Neurochem Int. 2019;125:57–66. doi:10.1016/j.neuint.2019.02.008
   PubMed Web of Science ®Google Scholar
• Talia S, Benarous K, Lamrani M, Yousfi M. Lepidine B from Lepidium sativum seeds as multi-functional anti- alzheimer’s disease agent: in vitro and in silico studies. Curr Comput Aided Drug Des. 2021;17(3):360–377. doi:10.2174/1573409916666200302120305
   PubMed Web of Science ®Google Scholar
• Chicca A, Marazzi J, Gertsch J. The antinociceptive triterpene β-amyrin inhibits 2-arachidonoylglycerol (2-AG) hydrolysis without directly targeting cannabinoid receptors. Br J Pharmacol. 2012;167(8):1596–1608. doi:10.1111/j.1476-5381.2012.02059.x
   PubMed Web of Science ®Google Scholar
• Vecchiarelli HA, Morena M, Lee TTY, et al. Sex and stressor modality influence acute stress-induced dynamic changes in corticolimbic endocannabinoid levels in adult Sprague Dawley rats. Neurobiol Stress. 2022;20:100470. doi:10.1016/j.ynstr.2022.100470
   PubMed Web of Science ®Google Scholar
• Botsford C, Brellenthin AG, Cisler JM, Hillard CJ, Koltyn KF, Crombie KM. Circulating endocannabinoids and psychological outcomes in women with PTSD. J Anxiety Disord. 2023;93:102656. doi:10.1016/j.janxdis.2022.102656
   PubMed Web of Science ®Google Scholar
• Rubino T, Realini N, Castiglioni C, et al. Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. Cereb Cortex. 2008;18(6):1292–1301. doi:10.1093/cercor/bhm161
   PubMed Web of Science ®Google Scholar
• Tevosian M, Todorov H, Lomazzo E, et al. NAPE-PLD deletion in stress-TRAPed neurons results in an anxiogenic phenotype. Transl Psychiatry. 2023;13(1):152. doi:10.1038/s41398-023-02448-9
   PubMed Web of Science ®Google Scholar
• Hill MN, Kumar SA, Filipski SB, et al. Disruption of fatty acid amide hydrolase activity prevents the effects of chronic stress on anxiety and amygdalar microstructure. Mol Psychiatry. 2013;18(10):1125–1135. doi:10.1038/mp.2012.90
   PubMed Web of Science ®Google Scholar
• Stopponi S, Fotio Y, Domi A, et al. Inhibition of fatty acid amide hydrolase in the central amygdala alleviates co-morbid expression of innate anxiety and excessive alcohol intake. Addict Biol. 2018;23(6):1223–1232. doi:10.1111/adb.12573
   PubMed Web of Science ®Google Scholar
• Postnov A, Schmidt ME, Pemberton DJ, et al. Fatty acid amide hydrolase inhibition by JNJ-42165279: a multiple-ascending dose and a positron emission tomography study in healthy volunteers. Clin Transl Sci. 2018;11(4):397–404. doi:10.1111/cts.12548
   PubMed Web of Science ®Google Scholar
• Paulus MP, Stein MB, Simmons AN, Risbrough VB, Halter R, Chaplan SR. The effects of FAAH inhibition on the neural basis of anxiety-related processing in healthy male subjects: a randomized clinical trial. Neuropsychopharmacol. 2021;46(5):1011–1019. doi:10.1038/s41386-020-00936-w
   PubMed Web of Science ®Google Scholar
• Li GL, Winter H, Arends R, et al. Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects. Br J Clin Pharmacol. 2012;73(5):706–716. doi:10.1111/j.1365-2125.2011.04137.x
   PubMed Web of Science ®Google Scholar
• Mayo LM, Asratian A, Lindé J, et al. Elevated anandamide, enhanced recall of fear extinction, and attenuated stress responses following inhibition of fatty acid amide hydrolase: a randomized, controlled experimental medicine trial. Biol Psychiatry. 2020;87(6):538–547. doi:10.1016/j.biopsych.2019.07.034
   PubMed Web of Science ®Google Scholar
• D’Souza DC, Cortes-Briones J, Creatura G, et al. Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. Lancet Psychiatry. 2019;6(1):35–45. doi:10.1016/S2215-0366(18)30427-9
   PubMed Web of Science ®Google Scholar
• Zimmermann T, Bartsch JC, Beer A, et al. Impaired anandamide/palmitoylethanolamide signaling in hippocampal glutamatergic neurons alters synaptic plasticity, learning, and emotional responses. Neuropsychopharmacology. 2019;44(8):1377–1388. doi:10.1038/s41386-018-0274-7
   PubMed Web of Science ®Google Scholar
• Fusse EJ, Scarante FF, Vicente MA, et al. Anxiogenic doses of rapamycin prevent URB597-induced anti-stress effects in socially defeated mice. Neurosci Lett. 2024;818:137519. doi:10.1016/j.neulet.2023.137519
   PubMed Web of Science ®Google Scholar
• Borges-Assis AB, Uliana DL, Hott SC, Guimarães FS, Lisboa SF, Resstel LBM. Bed nucleus of the stria terminalis CB1 receptors and the FAAH enzyme modulate anxiety behavior depending on previous stress exposure. Prog Neuropsychopharmacol Biol Psychiatry. 2023;125:110739. doi:10.1016/j.pnpbp.2023.110739
   PubMed Web of Science ®Google Scholar
• Danandeh A, Vozella V, Lim J, et al. Effects of fatty acid amide hydrolase inhibitor URB597 in a rat model of trauma-induced long-term anxiety. Psychopharmacology. 2018;235(11):3211–3221. doi:10.1007/s00213-018-5020-7
   PubMed Web of Science ®Google Scholar
• Flannery LE, Kerr DM, Finn DP, Roche M. FAAH inhibition attenuates TLR3-mediated hyperthermia, nociceptive- and anxiety-like behavior in female rats. Behav Brain Res. 2018;353:11–20. doi:10.1016/j.bbr.2018.06.030
   PubMed Web of Science ®Google Scholar
• de Ceglia M, Micioni Di Bonaventura MV, Romano A, et al. Anxiety associated with palatable food withdrawal is reversed by the selective FAAH inhibitor PF-3845: a regional analysis of the contribution of endocannabinoid signaling machinery. Int J Eat Disord. 2023;56(6):1098–1113. doi:10.1002/eat.23917
   PubMed Web of Science ®Google Scholar
• Bluett RJ, Gamble-George JC, Hermanson DJ, Hartley ND, Marnett LJ, Patel S. Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation. Transl Psychiatry. 2014;4(7):e408. doi:10.1038/tp.2014.53
   PubMedGoogle Scholar
• Carnevali L, Barbetti M, Fotio Y, et al. Enhancement of peripheral fatty acyl ethanolamide signaling prevents stress-induced social avoidance and anxiety-like behaviors in male rats. Psychopharmacology. 2023. doi:10.1007/s00213-023-06473-w
   PubMed Web of Science ®Google Scholar
• Vecchiarelli HA, Morena M, Keenan CM, et al. Comorbid anxiety-like behavior in a rat model of colitis is mediated by an upregulation of corticolimbic fatty acid amide hydrolase. Neuropsychopharmacology. 2021;46(5):992–1003. doi:10.1038/s41386-020-00939-7
   PubMed Web of Science ®Google Scholar
• Marco EM, Rapino C, Caprioli A, Borsini F, Laviola G, Maccarrone M. Potential therapeutic value of a novel FAAH inhibitor for the treatment of anxiety. PLoS One. 2015;10(9):e0137034. doi:10.1371/journal.pone.0137034
   PubMed Web of Science ®Google Scholar
• Silva HH, Tavares V, Neto BV, Cerqueira F, Medeiros R, Silva MRG. FAAH rs324420 polymorphism: biological pathways, impact on elite athletic performance and insights for sport medicine. Genes. 2023;14(10):1946. doi:10.3390/genes14101946
   PubMed Web of Science ®Google Scholar
• Spohrs J, Ulrich M, Grön G, Plener PL, Abler B. FAAH polymorphism (rs324420) modulates extinction recall in healthy humans: an fMRI study. Eur Arch Psychiatry Clin Neurosci. 2022;272(8):1495–1504. doi:10.1007/s00406-021-01367-4
   PubMed Web of Science ®Google Scholar
• Sisk LM, Rapuano KM, Conley MI, et al. Genetic variation in endocannabinoid signaling is associated with differential network-level functional connectivity in youth. J Neurosci Res. 2022;100(3):731–743. doi:10.1002/jnr.24946
   PubMed Web of Science ®Google Scholar
• Dincheva I, Drysdale AT, Hartley CA, et al. FAAH genetic variation enhances fronto-amygdala function in mouse and human. Nat Commun. 2015;6:6395. doi:10.1038/ncomms7395
   PubMed Web of Science ®Google Scholar
• Marusak HA, Evanski J, Desai S, Rabinak CA. Impact of childhood trauma exposure, genetic variation in endocannabinoid signaling, and anxiety on frontolimbic pathways in children. Cannabis Cannabinoid Res. 2023;8(6):1079–1089. doi:10.1089/can.2022.0144
   PubMedGoogle Scholar
• Hillard CJ. Chapter one - the endocannabinoid signaling system in the CNS: a primer. In: Parsons L, Hill M editors. International Review of Neurobiology. Vol 125. Endocannabinoids. Academic Press; 2015:1–47. doi:10.1016/bs.irn.2015.10.001
   Google Scholar
• Yasmin F, Colangeli R, Morena M, et al. Stress-induced modulation of endocannabinoid signaling leads to delayed strengthening of synaptic connectivity in the amygdala. Proc Natl Acad Sci. 2020;117(1):650–655. doi:10.1073/pnas.1910322116
   PubMed Web of Science ®Google Scholar
• Gulyas AI, Cravatt BF, Bracey MH, et al. Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. Eur J Neurosci. 2004;20(2):441–458. doi:10.1111/j.1460-9568.2004.03428.x
   PubMed Web of Science ®Google Scholar
• Morena M, Patel S, Bains JS, Hill MN. Neurobiological Interactions Between Stress and the Endocannabinoid System. Neuropsychopharmacol. 2016;41(1):80–102. doi:10.1038/npp.2015.166
   PubMed Web of Science ®Google Scholar
• Alugubelly N, Mohammed AN, Carr RL. Persistent proteomic changes in glutamatergic and GABAergic signaling in the amygdala of adolescent rats exposed to chlorpyrifos as juveniles. Neurotoxicology. 2021;85:234–244. doi:10.1016/j.neuro.2021.05.012
   PubMed Web of Science ®Google Scholar
• Rl C, A N, de L K, et al.. Inhibition of fatty acid amide hydrolase by chlorpyrifos in juvenile rats results in altered exploratory and social behavior as adolescents. Neurotoxicology. 2020:77. doi:10.1016/j.neuro.2020.01.002
   Web of Science ®Google Scholar
• Duan T, Gu N, Wang Y, et al. Fatty acid amide hydrolase inhibitors produce rapid anti-anxiety responses through amygdala long-term depression in male rodents. J Psychiatry Neurosci. 2017;42(4):230–241. doi:10.1503/jpn.160116
   PubMed Web of Science ®Google Scholar
• Pavón FJ, Serrano A, Stouffer DG, et al. Ethanol-induced alterations in endocannabinoids and relevant neurotransmitters in the nucleus accumbens of fatty acid amide hydrolase knockout mice. Addict Biol. 2019;24(6):1204–1215. doi:10.1111/adb.12695
   PubMed Web of Science ®Google Scholar
• Rossi S, De Chiara V, Musella A, et al. Preservation of striatal cannabinoid CB1 receptor function correlates with the antianxiety effects of fatty acid amide hydrolase inhibition. Mol Pharmacol. 2010;78(2):260–268. doi:10.1124/mol.110.064196
   PubMed Web of Science ®Google Scholar
• Aguilera-Portillo G, Rangel-López E, Villeda-Hernández J, et al. The pharmacological inhibition of fatty acid amide hydrolase prevents excitotoxic damage in the rat striatum: possible involvement of CB1 receptors regulation. Mol Neurobiol. 2019;56(2):844–856. doi:10.1007/s12035-018-1129-2
   PubMed Web of Science ®Google Scholar
• Kerr DM, Burke NN, Ford GK, et al. Pharmacological inhibition of endocannabinoid degradation modulates the expression of inflammatory mediators in the hypothalamus following an immunological stressor. Neuroscience. 2012;204:53–63. doi:10.1016/j.neuroscience.2011.09.032
   PubMed Web of Science ®Google Scholar
• Doenni VM, Gray JM, Song CM, Patel S, Hill MN, Pittman QJ. Deficient adolescent social behavior following early-life inflammation is ameliorated by augmentation of anandamide signaling. Brain Behav Immun. 2016;58:237–247. doi:10.1016/j.bbi.2016.07.152
   PubMed Web of Science ®Google Scholar
• Grieco M, De Caris MG, Maggi E, et al. Fatty Acid Amide Hydrolase (FAAH) inhibition modulates amyloid-beta-induced microglia polarization. Int J Mol Sci. 2021;22(14):7711. doi:10.3390/ijms22147711
   PubMed Web of Science ®Google Scholar
• Malek N, Popiolek-Barczyk K, Mika J, Przewlocka B, Starowicz K. Anandamide, acting via CB2 receptors, alleviates LPS-induced neuroinflammation in rat primary microglial cultures. Neural Plast. 2015;2015:130639. doi:10.1155/2015/130639
   PubMed Web of Science ®Google Scholar
• Tanaka M, Yagyu K, Sackett S, Zhang Y. Anti-inflammatory effects by pharmacological inhibition or knockdown of fatty acid amide hydrolase in BV2 microglial cells. Cells. 2019;8(5):491. doi:10.3390/cells8050491
   PubMed Web of Science ®Google Scholar
• Rivera P, Del Mar Fernández-Arjona M, Silva-Peña D, et al. Pharmacological blockade of fatty acid amide hydrolase (FAAH) by URB597 improves memory and changes the phenotype of hippocampal microglia despite ethanol exposure. Biochem. Pharmacol. 2018;157:244–257. doi:10.1016/j.bcp.2018.08.005
   PubMed Web of Science ®Google Scholar
• Tchantchou F, Tucker LB, Fu AH, et al. The fatty acid amide hydrolase inhibitor PF-3845 promotes neuronal survival, attenuates inflammation and improves functional recovery in mice with traumatic brain injury. Neuropharmacology. 2014;85:427–439. doi:10.1016/j.neuropharm.2014.06.006
   PubMed Web of Science ®Google Scholar
• Henry RJ, Kerr DM, Finn DP, Roche M. FAAH-mediated modulation of TLR3-induced neuroinflammation in the rat hippocampus. J Neuroimmunol. 2014;276(1–2):126–134. doi:10.1016/j.jneuroim.2014.09.002
   PubMed Web of Science ®Google Scholar
• Zhu Y, Zhang H, Mao H, et al. FAAH served a key membrane-anchoring and stabilizing role for NLRP3 protein independently of the endocannabinoid system. Cell Death Differ. 2023;30(1):168–183. doi:10.1038/s41418-022-01054-4
   PubMed Web of Science ®Google Scholar
• Abelson JL, Liberzon I, Young EA, Khan S. Cognitive modulation of the endocrine stress response to a pharmacological challenge in normal and panic disorder subjects. Arch Gen Psychiatry. 2005;62(6):668–675. doi:10.1001/archpsyc.62.6.668
   PubMed Web of Science ®Google Scholar
• Hill MN, McLaughlin RJ, Bingham B, et al. Endogenous cannabinoid signaling is essential for stress adaptation. Proc Natl Acad Sci U S A. 2010;107(20):9406–9411. doi:10.1073/pnas.0914661107
   PubMed Web of Science ®Google Scholar
• Hill MN, McLaughlin RJ, Morrish AC, et al. Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic-pituitary-adrenal axis. Neuropsychopharmacology. 2009;34(13):2733–2745. doi:10.1038/npp.2009.114
   PubMed Web of Science ®Google Scholar
• Newsom RJ, Osterlund C, Masini CV, Day HE, Spencer RL, Campeau S. Cannabinoid receptor type 1 antagonism significantly modulates basal and loud noise induced neural and hypothalamic-pituitary-adrenal axis responses in male Sprague-Dawley rats. Neuroscience. 2012;204:64–73. doi:10.1016/j.neuroscience.2011.11.043
   PubMed Web of Science ®Google Scholar
• Haller J, Barna I, Barsvari B, et al. Interactions between environmental aversiveness and the anxiolytic effects of enhanced cannabinoid signaling by FAAH inhibition in rats. Psychopharmacology. 2009;204(4):607–616. doi:10.1007/s00213-009-1494-7
   PubMed Web of Science ®Google Scholar
• Bedse G, Colangeli R, Lavecchia AM, et al. Role of the basolateral amygdala in mediating the effects of the fatty acid amide hydrolase inhibitor URB597 on HPA axis response to stress. Eur Neuropsychopharmacol. 2014;24(9):1511–1523. doi:10.1016/j.euroneuro.2014.07.005
   PubMed Web of Science ®Google Scholar
• Gray JM, Vecchiarelli HA, Morena M, et al. Corticotropin-releasing hormone drives anandamide hydrolysis in the amygdala to promote anxiety. J Neurosci. 2015;35(9):3879–3892. doi:10.1523/JNEUROSCI.2737-14.2015
   PubMed Web of Science ®Google Scholar
• Gray JM, Wilson CD, Lee TTY, et al. Sustained glucocorticoid exposure recruits cortico-limbic CRH signaling to modulate endocannabinoid function. Psychoneuroendocrinology. 2016;66:151–158. doi:10.1016/j.psyneuen.2016.01.004
   PubMed Web of Science ®Google Scholar
• Duranti A, Beldarrain G, Álvarez A, et al. The endocannabinoid system as a target for neuroprotection/neuroregeneration in perinatal hypoxic–ischemic brain injury. Biomedicines. 2022;11(1):28. doi:10.3390/biomedicines11010028
   PubMed Web of Science ®Google Scholar
• Oddi S, Fiorenza MT, Maccarrone M. Endocannabinoid signaling in adult hippocampal neurogenesis: a mechanistic and integrated perspective. Prog Lipid Res. 2023;91:101239. doi:10.1016/j.plipres.2023.101239
   PubMed Web of Science ®Google Scholar
• Fogaça MV, Campos AC, Coelho LD, Duman RS, Guimarães FS. The anxiolytic effects of cannabidiol in chronically stressed mice are mediated by the endocannabinoid system: role of neurogenesis and dendritic remodeling. Neuropharmacology. 2018;135:22–33. doi:10.1016/j.neuropharm.2018.03.001
   PubMed Web of Science ®Google Scholar
• Avraham HK, Jiang S, Fu Y, et al. Impaired neurogenesis by HIV-1-Gp120 is rescued by genetic deletion of fatty acid amide hydrolase enzyme. Br J Pharmacol. 2015;172(19):4603–4614. doi:10.1111/bph.12657
   PubMed Web of Science ®Google Scholar
• Segev A, Korem N, Mizrachi Zer-Aviv T, et al. Role of endocannabinoids in the hippocampus and amygdala in emotional memory and plasticity. Neuropsychopharmacology. 2018;43(10):2017–2027. doi:10.1038/s41386-018-0135-4
   PubMed Web of Science ®Google Scholar
• Kathuria S, Gaetani S, Fegley D, et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med. 2003;9(1):76–81. doi:10.1038/nm803
   PubMed Web of Science ®Google Scholar
• Koehl M, Ladevèze E, Catania C, Cota D, Abrous DN. Inhibition of mTOR signaling by genetic removal of p70 S6 kinase 1 increases anxiety-like behavior in mice. Transl Psychiatry. 2021;11(1):165. doi:10.1038/s41398-020-01187-5
   PubMed Web of Science ®Google Scholar
• Tanaka M, Yamada S, Watanabe Y. The Role of Neuropeptide Y in the Nucleus Accumbens. Int J Mol Sci. 2021;22(14):7287. doi:10.3390/ijms22147287
   PubMed Web of Science ®Google Scholar
• Amstadter AB, Koenen KC, Ruggiero KJ, et al. NPY moderates the relation between hurricane exposure and generalized anxiety disorder in an epidemiologic sample of hurricane-exposed adults. Depress Anxiety. 2010;27(3):270–275. doi:10.1002/da.20648
   PubMed Web of Science ®Google Scholar
• Decressac M, Barker RA. Neuropeptide Y and its role in CNS disease and repair. Exp Neurol. 2012;238(2):265–272. doi:10.1016/j.expneurol.2012.09.004
   PubMed Web of Science ®Google Scholar
• Molosh AI, Sajdyk TJ, Truitt WA, Zhu W, Oxford GS, Shekhar A. NPY Y1 receptors differentially modulate GABAA and NMDA receptors via divergent signal-transduction pathways to reduce excitability of amygdala neurons. Neuropsychopharmacology. 2013;38(7):1352–1364. doi:10.1038/npp.2013.33
   PubMed Web of Science ®Google Scholar
• Maymon N, Mizrachi Zer-Aviv T, Sabban EL, Akirav I. Neuropeptide Y and cannabinoids interaction in the amygdala after exposure to shock and reminders model of PTSD. Neuropharmacology. 2020;162:107804. doi:10.1016/j.neuropharm.2019.107804
   PubMed Web of Science ®Google Scholar
• Greco R, Demartini C, Zanaboni AM, et al. Potentiation of endocannabinoids and other lipid amides prevents hyperalgesia and inflammation in a pre-clinical model of migraine. J Headache Pain. 2022;23(1):79. doi:10.1186/s10194-022-01449-1
   PubMed Web of Science ®Google Scholar
• Fotio Y, Mabou Tagne A, Jung KM, Piomelli D. Fatty acid amide hydrolase inhibition alleviates anxiety-like symptoms in a rat model used to study post-traumatic stress disorder. Psychopharmacology. 2023. doi:10.1007/s00213-023-06358-y
   Web of Science ®Google Scholar
• Shang Y, Wang M, Hao Q, et al. Development of indole-2-carbonyl piperazine urea derivatives as selective FAAH inhibitors for efficient treatment of depression and pain. Bioorg Chem. 2022;128:106031. doi:10.1016/j.bioorg.2022.106031
   PubMed Web of Science ®Google Scholar
• Gur Maz T, Turanlı S, Caliskan HB, Çalışkan B, Banoglu E. Development and molecular modeling studies of new thiadiazole piperazine urea derivatives as potential fatty acid amide hydrolase inhibitors. Arch Pharm. 2022;355(8):e2200082. doi:10.1002/ardp.202200082
   PubMed Web of Science ®Google Scholar
• Keith JM, Jones W, Pierce JM, et al. Heteroarylureas with fused bicyclic diamine cores as inhibitors of fatty acid amide hydrolase. Bioorg Med Chem Lett. 2020;30(20):127463. doi:10.1016/j.bmcl.2020.127463
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Tripathi RKP, Ayyannan SR. Scaffold hopping-guided design of some isatin based rigid analogs as fatty acid amide hydrolase inhibitors: synthesis and evaluation. Biomed Pharmacother. 2018;107:1611–1623. doi:10.1016/j.biopha.2018.08.125
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Ayyannan SR. Lead optimization study on indoline-2,3-dione derivatives as potential fatty acid amide hydrolase inhibitors. J Biomol Struct Dyn. 2023;41(19):9632–9650. doi:10.1080/07391102.2022.2145372
   PubMed Web of Science ®Google Scholar
• Patel JZ, Parkkari T, Laitinen T, et al. Chiral 1,3,4-oxadiazol-2-ones as highly selective FAAH inhibitors. J Med Chem. 2013;56(21):8484–8496. doi:10.1021/jm400923s
   PubMed Web of Science ®Google Scholar
• Greco R, Francavilla M, Demartini C, et al. Activity of FAAH-Inhibitor JZP327A in an Experimental Rat Model of Migraine. Int J Mol Sci. 2023;24(12):10102. doi:10.3390/ijms241210102
   PubMed Web of Science ®Google Scholar
• Papa A, Pasquini S, Galvani F, et al. Development of potent and selective FAAH inhibitors with improved drug-like properties as potential tools to treat neuroinflammatory conditions. Eur J Med Chem. 2023;246:114952. doi:10.1016/j.ejmech.2022.114952
   PubMed Web of Science ®Google Scholar
• Zięba A, Laitinen T, Patel JZ, Poso A, Kaczor AA. Docking-based 3D-QSAR studies for 1,3,4-oxadiazol-2-one derivatives as FAAH inhibitors. Int J Mol Sci. 2021;22(11):6108. doi:10.3390/ijms22116108
   PubMed Web of Science ®Google Scholar
• Lorca M, Valdes Y, Chung H, Romero-Parra J, Pessoa-Mahana CD, Mella J. Three-Dimensional Quantitative Structure-Activity Relationships (3D-QSAR) on a Series of Piperazine-Carboxamides Fatty Acid Amide Hydrolase (FAAH) inhibitors as a useful tool for the design of new cannabinoid ligands. Int J Mol Sci. 2019;20(10):2510. doi:10.3390/ijms20102510
   PubMed Web of Science ®Google Scholar
• Zanfirescu A, Nitulescu G, Mihai DP, Nitulescu GM. Identifying FAAH inhibitors as new therapeutic options for the treatment of chronic pain through drug repurposing. Pharmaceuticals. 2021;15(1):38. doi:10.3390/ph15010038
   Web of Science ®Google Scholar
• Deplano A, Karlsson J, Svensson M, et al. Exploring the fatty acid amide hydrolase and cyclooxygenase inhibitory properties of novel amide derivatives of ibuprofen. J Enzyme Inhib Med Chem. 2020;35(1):815–823. doi:10.1080/14756366.2020.1743283
   PubMed Web of Science ®Google Scholar
• Deplano A, Karlsson J, Moraca F, et al. Design, synthesis and in vitro and in vivo biological evaluation of flurbiprofen amides as new fatty acid amide hydrolase/cyclooxygenase-2 dual inhibitory potential analgesic agents. J Enzyme Inhib Med Chem. 2021;36(1):940–953. doi:10.1080/14756366.2021.1875459
   PubMed Web of Science ®Google Scholar
• Montanari S, Scalvini L, Bartolini M, et al. Fatty Acid Amide Hydrolase (FAAH), Acetylcholinesterase (AChE), and Butyrylcholinesterase (BuChE): networked targets for the development of carbamates as potential anti-Alzheimer’s Disease agents. J Med Chem. 2016;59(13):6387–6406. doi:10.1021/acs.jmedchem.6b00609
   PubMed Web of Science ®Google Scholar
• Maleki MF, Nadri H, Kianfar M, et al. Design and synthesis of new carbamates as inhibitors for fatty acid amide hydrolase and cholinesterases: molecular dynamic, in vitro and in vivo studies. Bioorg Chem. 2021;109:104684. doi:10.1016/j.bioorg.2021.104684
   PubMed Web of Science ®Google Scholar
• Wilt S, Kodani S, Le TNH, et al. Development of multitarget inhibitors for the treatment of pain: design, synthesis, biological evaluation and molecular modeling studies. Bioorg Chem. 2020;103:104165. doi:10.1016/j.bioorg.2020.104165
   PubMed Web of Science ®Google Scholar
• Cammarota M, Ferlenghi F, Vacondio F, et al. Combined targeting of fatty acid amide hydrolase and melatonin receptors promotes neuroprotection and stimulates inflammation resolution in rats. Br J Pharmacol. 2023;180(10):1316–1338. doi:10.1111/bph.16014
   PubMed Web of Science ®Google Scholar
• Intranuovo F, Brunetti L, DelRe P, et al. Development of N-(1-Adamantyl)benzamides as novel anti-inflammatory multitarget agents acting as dual modulators of the cannabinoid CB2 receptor and fatty acid amide hydrolase. J Med Chem. 2023;66(1):235–250. doi:10.1021/acs.jmedchem.2c01084
   PubMed Web of Science ®Google Scholar
• Wagenlehner FME, van Till JWO, Houbiers JGA, et al. Fatty acid amide hydrolase inhibitor treatment in men with chronic prostatitis/chronic pelvic pain syndrome: an adaptive double-blind, randomized controlled trial. Urology. 2017;103:191–197. doi:10.1016/j.urology.2017.02.029
   PubMed Web of Science ®Google Scholar
• Demartini C, Greco R, Zanaboni AM, Francavilla M, Facchetti S, Tassorelli C. URB937 prevents the development of mechanical allodynia in male rats with trigeminal neuralgia. Pharmaceuticals. 2023;16(11):1626. doi:10.3390/ph16111626
   Web of Science ®Google Scholar
• Zhang D, Saraf A, Kolasa T, et al. Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets. Neuropharmacology. 2007;52(4):1095–1105. doi:10.1016/j.neuropharm.2006.11.009
   PubMed Web of Science ®Google Scholar
• Kerbrat A, Ferré JC, Fillatre P, et al. Acute neurologic disorder from an inhibitor of fatty acid amide hydrolase. N Engl J Med. 2016;375(18):1717–1725. doi:10.1056/NEJMoa1604221
   PubMed Web of Science ®Google Scholar
• van Esbroeck ACM, Janssen APA, Cognetta AB, et al. Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474. Science. 2017;356(6342):1084–1087. doi:10.1126/science.aaf7497
   PubMed Web of Science ®Google Scholar
• Otrubova K, Chatterjee S, Ghimire S, Cravatt BF, Boger DL. N-Acyl pyrazoles: effective and tunable inhibitors of serine hydrolases. Bioorg Med Chem. 2019;27(8):1693–1703. doi:10.1016/j.bmc.2019.03.020
   PubMed Web of Science ®Google Scholar
• Lamani M, Malamas MS, Farah SI, et al. Piperidine and piperazine inhibitors of fatty acid amide hydrolase targeting excitotoxic pathology. Bioorg Med Chem. 2019;27(23):115096. doi:10.1016/j.bmc.2019.115096
   PubMed Web of Science ®Google Scholar
• Thors L, Eriksson J, Fowler CJ. Inhibition of the cellular uptake of anandamide by genistein and its analogue daidzein in cells with different levels of fatty acid amide hydrolase-driven uptake. Br J Pharmacol. 2007;152(5):744–750. doi:10.1038/sj.bjp.0707401
   PubMed Web of Science ®Google Scholar
• Ahmad H, Rauf K, Zada W, et al. Kaempferol facilitated extinction learning in contextual fear conditioned rats via inhibition of fatty-acid amide hydrolase. Molecules. 2020;25(20):4683. doi:10.3390/molecules25204683
   PubMed Web of Science ®Google Scholar
• Zada W, VanRyzin JW, Perez‐Pouchoulen M, et al. Fatty acid amide hydrolase inhibition and N‐arachidonoylethanolamine modulation by isoflavonoids: a novel target for upcoming antidepressants. Pharmacol Res Perspect. 2022;10(5):e00999. doi:10.1002/prp2.999
   PubMed Web of Science ®Google Scholar
• Alasmari M, Bӧhlke M, Kelley C, Maher T, Pino-Figueroa A. Inhibition of Fatty Acid Amide Hydrolase (FAAH) by macamides. Mol Neurobiol. 2019;56(3):1770–1781. doi:10.1007/s12035-018-1115-8
   PubMed Web of Science ®Google Scholar
• Almukadi H, Wu H, Böhlke M, Kelley CJ, Maher TJ, Pino-Figueroa A. The macamide N-3-methoxybenzyl-linoleamide is a time-dependent fatty acid amide hydrolase (FAAH) inhibitor. Mol Neurobiol. 2013;48(2):333–339. doi:10.1007/s12035-013-8499-2
   PubMed Web of Science ®Google Scholar
• Police A, Shankar VK, Pandey P, Rangappa S, Doerksen RJ, Narasimha Murthy S. Novel topical anandamide formulation for alleviating peripheral neuropathic pain. Int J Pharm. 2023;641:123085. doi:10.1016/j.ijpharm.2023.123085
   PubMedGoogle Scholar
• Shanmugasundaram D, Roza JM. Effect of broad-spectrum hemp extract on neurobehavioral activity on the immobilization stress-induced model in Sprague Dawley rats. ScientificWorldJournal. 2023;2023:3425576. doi:10.1155/2023/3425576
   PubMedGoogle Scholar
• Lin YX, Sun JT, Liao ZZ, et al. Triterpenoids from the fruiting bodies of Ganoderma lucidum and their inhibitory activity against FAAH. Fitoterapia. 2022;158:105161. doi:10.1016/j.fitote.2022.105161
   PubMed Web of Science ®Google Scholar
• Li DW, Liu M, Leng YQ, et al. Lanostane triterpenoids from Ganoderma lucidum and their inhibitory effects against FAAH. Phytochemistry. 2022;203:113339. doi:10.1016/j.phytochem.2022.113339
   PubMed Web of Science ®Google Scholar
• Thors L, Alajakku K, Fowler CJ. The “specific” tyrosine kinase inhibitor genistein inhibits the enzymic hydrolysis of anandamide: implications for anandamide uptake. Br J Pharmacol. 2007;150(7):951–960. doi:10.1038/sj.bjp.0707172
   PubMed Web of Science ®Google Scholar
• El-Mekkawy S, Shahat AA, Alqahtani AS, et al. A polyphenols-rich extract from Moricandia sinaica Boiss. Exhibits analgesic, anti-inflammatory and antipyretic activities in vivo. Molecules. 2020;25(21):5049. doi:10.3390/molecules25215049
   PubMed Web of Science ®Google Scholar
• Thors L, Belghiti M, Fowler CJ. Inhibition of fatty acid amide hydrolase by kaempferol and related naturally occurring flavonoids. Br J Pharmacol. 2008;155(2):244–252. doi:10.1038/bjp.2008.237
   PubMed Web of Science ®Google Scholar
• Mariano A, Di Sotto A, Leopizzi M, et al. Antiarthritic effects of a root extract from Harpagophytum procumbens DC: novel insights into the molecular mechanisms and possible bioactive phytochemicals. Nutrients. 2020;12(9):2545. doi:10.3390/nu12092545
   PubMed Web of Science ®Google Scholar
• Gonçalves ECD, Assis PM, Junqueira LA, et al. Citral inhibits the inflammatory response and hyperalgesia in mice: the role of TLR4, TLR2/Dectin-1, and CB2 cannabinoid receptor/ATP-sensitive K+ channel pathways. J Nat Prod. 2020;83(4):1190–1200. doi:10.1021/acs.jnatprod.9b01134
   PubMed Web of Science ®Google Scholar
• El-Alfy AT, Abourashed EA, Patel C, Mazhari N, An H, Jeon A. Phenolic compounds from nutmeg (Myristica fragrans Houtt.) inhibit the endocannabinoid-modulating enzyme fatty acid amide hydrolase. J Pharm Pharmacol. 2019;71(12):1879–1889. doi:10.1111/jphp.13174
   PubMed Web of Science ®Google Scholar
• Sanna MD, Les F, Lopez V, Galeotti N. Lavender (Lavandula angustifolia Mill.) essential oil alleviates neuropathic pain in mice with spared nerve injury. Front Pharmacol. 2019;10:472. doi:10.3389/fphar.2019.00472
   PubMed Web of Science ®Google Scholar
• De Petrocellis L, Ligresti A, Moriello AS, et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol. 2011;163(7):1479–1494. doi:10.1111/j.1476-5381.2010.01166.x
   PubMed Web of Science ®Google Scholar
• Capasso R, Borrelli F, Aviello G, et al. Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice. Br J Pharmacol. 2008;154(5):1001–1008. doi:10.1038/bjp.2008.177
   PubMed Web of Science ®Google Scholar
• Li D, Leng Y, Liao Z, et al. Nor-triterpenoids from the fruiting bodies of Ganoderma lucidum and their inhibitory activity against FAAH. Nat Prod Res. 2023;37(4):579–585. doi:10.1080/14786419.2022.2078817
   PubMed Web of Science ®Google Scholar
• Chicca A, Caprioglio D, Minassi A, et al. Functionalization of β-caryophyllene generates novel polypharmacology in the endocannabinoid system. ACS Chem Biol. 2014;9(7):1499–1507. doi:10.1021/cb500177c
   PubMed Web of Science ®Google Scholar
• Irrera N, D’Ascola A, Pallio G, et al. β-Caryophyllene Mitigates Collagen Antibody Induced Arthritis (CAIA) in mice through a cross-talk between CB2 and PPAR-γ receptors. Biomolecules. 2019;9(8):326. doi:10.3390/biom9080326
   PubMed Web of Science ®Google Scholar
• Wu H, Kelley CJ, Pino-Figueroa A, Vu HD, Maher TJ. Macamides and their synthetic analogs: evaluation of in vitro FAAH inhibition. Bioorg Med Chem. 2013;21(17):5188–5197. doi:10.1016/j.bmc.2013.06.034
   PubMed Web of Science ®Google Scholar
• Taboada-Rosell K, Castro-García FA, Medina-Saldivar C, Cruz-Visalaya SR, Pacheco-Otalora LF. The novel FAAH inhibitor, MCH1, reduces the infarction area in the motor cortex-related region but does not affect the sensorimotor function or memory and spatial learning in rats exposed to transient middle cerebral artery occlusion. Brain Res. 2024;1822:148636. doi:10.1016/j.brainres.2023.148636
   PubMed Web of Science ®Google Scholar
• Zhang ZW, Han P, Fu J, et al. Gut microbiota-based metabolites of Xiaoyao Pills (a typical Traditional Chinese medicine) ameliorate depression by inhibiting fatty acid amide hydrolase levels in brain. J Ethnopharmacol. 2023;313:116555. doi:10.1016/j.jep.2023.116555
   PubMed Web of Science ®Google Scholar
• Samandar F, Tehranizadeh ZA, Saberi MR, Chamani J. CB1 as a novel target for Ginkgo biloba’s terpene trilactone for controlling chemotherapy-induced peripheral neuropathy (CIPN). J Mol Model. 2022;28(9):283. doi:10.1007/s00894-022-05284-8
   PubMed Web of Science ®Google Scholar
• Xie J, Li Y, Liang Y, Kui H, Wang C, Huang J. Integration of non-targeted metabolomics with network pharmacology deciphers the anxiolytic mechanisms of Platycladi Semen extracts in CUMS mice. J Ethnopharmacol. 2023;315:116571. doi:10.1016/j.jep.2023.116571
   PubMed Web of Science ®Google Scholar
• Tian X, Liu T, Li L, et al. Visual high-throughput screening for developing a fatty acid amide hydrolase natural inhibitor based on an enzyme-activated fluorescent probe. Anal Chem. 2020;92(14):9493–9500. doi:10.1021/acs.analchem.9b05826
   PubMed Web of Science ®Google Scholar
• Tian M, Tian Z, Yao D, et al. A NIR fluorescent probe for fatty acid amide hydrolase bioimaging and its application in development of inhibitors. J Mater Chem B. 2021;9(32):6460–6465. doi:10.1039/d1tb01054a
   PubMed Web of Science ®Google Scholar
• Della Pietra A, Krivoshein G, Ivanov K, et al. Potent dual MAGL/FAAH inhibitor AKU-005 engages endocannabinoids to diminish meningeal nociception implicated in migraine pain. J Headache Pain. 2023;24(1):38. doi:10.1186/s10194-023-01568-3
   PubMed Web of Science ®Google Scholar
• Dong B, Shilpa BM, Shah R, et al. Dual pharmacological inhibitor of endocannabinoid degrading enzymes reduces depressive-like behavior in female rats. J Psychiatr Res. 2020;120:103–112. doi:10.1016/j.jpsychires.2019.10.010
   PubMed Web of Science ®Google Scholar
• Adamson Barnes NS, Mitchell VA, Kazantzis NP, Vaughan CW. Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine neuropathic pain model. Br J Pharmacol. 2016;173(1):77–87. doi:10.1111/bph.13337
   PubMed Web of Science ®Google Scholar
• Toczek M, Ryszkiewicz P, Remiszewski P, et al. Weak hypotensive effect of chronic administration of the dual FAAH/MAGL inhibitor JZL195 in spontaneously hypertensive rats as revealed by area under the curve analysis. Int J Mol Sci. 2023;24(13):10942. doi:10.3390/ijms241310942
   PubMed Web of Science ®Google Scholar
• Abohalaka R, Karaman Y, Recber T, Onder SC, Nemutlu E, Bozkurt TE. Endocannabinoid metabolism inhibition ameliorates ovalbumin-induced allergic airway inflammation and hyperreactivity in Guinea pigs. Life Sci. 2022;306:120808. doi:10.1016/j.lfs.2022.120808
   PubMed Web of Science ®Google Scholar
• Manduca A, Morena M, Campolongo P, et al. Distinct roles of the endocannabinoids anandamide and 2-arachidonoylglycerol in social behavior and emotionality at different developmental ages in rats. Eur Neuropsychopharmacol. 2015;25(8):1362–1374. doi:10.1016/j.euroneuro.2015.04.005
   PubMed Web of Science ®Google Scholar
• Fowler CJ. Transport of endocannabinoids across the plasma membrane and within the cell. FEBS J. 2013;280(9):1895–1904. doi:10.1111/febs.12212
   PubMed Web of Science ®Google Scholar
• Nicolussi S, Gertsch J. Endocannabinoid transport revisited. Vitam Horm. 2015;98:441–485. doi:10.1016/bs.vh.2014.12.011
   PubMed Web of Science ®Google Scholar
• Jones MJ, Uzuneser TC, Clement T, et al. Inhibition of fatty acid binding protein-5 in the basolateral amygdala induces anxiolytic effects and accelerates fear memory extinction. Psychopharmacology. 2023. doi:10.1007/s00213-023-06468-7
   PubMed Web of Science ®Google Scholar
• Chicca A, Nicolussi S, Bartholomäus R, et al. Chemical probes to potently and selectively inhibit endocannabinoid cellular reuptake. Proc Natl Acad Sci U S A. 2017;114(25):E5006–E5015. doi:10.1073/pnas.1704065114
   PubMed Web of Science ®Google Scholar
• Bortolato M, Campolongo P, Mangieri RA, et al. Anxiolytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology. 2006;31(12):2652–2659. doi:10.1038/sj.npp.1301061
   PubMed Web of Science ®Google Scholar
• Kwee CMB, Leen NA, Van der Kamp RC, et al. Anxiolytic effects of endocannabinoid enhancing compounds: a systematic review and meta-analysis. Eur Neuropsychopharmacol. 2023;72:79–94. doi:10.1016/j.euroneuro.2023.04.001
   PubMed Web of Science ®Google Scholar